Lithuanians worry about fallout from Belarus sanctions
INTERVIEW: “The weekend’s protests were the Russian people's, not the opposition’s” – Maxim Reznik
Western Balkans citizens legally resident in EU equal to 14% of region’s population
International Ice Hockey Federation (IIHF) has stripped Belarus of the right to hold the World Championship this year
Russia's Sberbank makes a move in e-commerce with Goods.ru deal
Putin strikes a conciliatory tone in his World Economic Forum speech but warns of an “all against all” fight if tensions are ignored
OUTLOOK 2021 Russia
@russian_market sacked by UBS for supporting Navalny
Public support is collapsing for The People’s Servant Party
Ukraine’s industrial output jumped 4.8% y/y in December
State-owned Ukrgasbank signs off on convertible €30mn IFC loan ahead of its privatisation
National Bank of Ukraine retains a key policy rate at 6%, the outlook of the CPI deteriorates
Estonia's two big parties agree on grand coalition
VISEGRAD BLOG: Central Europe's populists need a new strategy for Biden
LONG READ: The oligarch problem
China to be excluded from Czech tender for new Dukovany nuclear unit
Czech billionaire Kellner´s PPF makes another bid for Moneta Money Bank
Czech MPs pass protectionist food law in violation of EU rules
M&A in Central and Eastern Europe fell 16% in value in 2020, says CMS report
Hungarian government plans to regulate big tech to stop 'ban' on rightwing views
Hungarian vehicle makers hit by supply chain shortage
Protests sweep Poland after government launches near-total abortion ban
Polish parcel locker operator InPost soars in Euronext Amsterdam debut
Polish industrial production continues boom in December
OUTLOOK 2021 Slovakia
BRICKS & MORTAR: Rosier future beckons for CEE retailers after year of change and disruption
FDI inflows to CEE down 58% in 1H20 but rebound expected
BALKAN BLOG: Only better waste management can clean rivers of trash
Pandemic pushes public debt close to 80% of GDP in Albania and Montenegro
BALKAN BLOG: Superstition and resentment surround vaccination plans
Albania needs reforms for e-commerce to thrive, says World Bank
Bosnia's exports in 2020 amounted to BAM10.5bn, trade deficit to BAM6.3bn
Bulgaria’s latest nuclear u-turn
Retailers and restaurant owners threaten protests in Bulgaria if reopening is delayed
Bulgaria's Biodit first company to IPO on new BEAM market
Spring lockdown caused spike in online transactions in Croatia
ING: Growth in the Balkans: from zero to hero again?
Labour demand down 28% y/y in Croatia in 2020
Kosovo’s biggest opposition party risks being unable to run in general election
OUTLOOK 2021 Moldova
Storming parliaments: New Europe's greatest hits
World Bank revises projection for Moldova’s 2020 GDP decline to 7.2%
Montenegro’s special prosecution probes finance minister over €750mn Eurobond issue
North Macedonia’s state-owned loss-makers await new owners
North Macedonia plans to cut personal income tax in IT sector to zero in 2023
Romanian cybersecurity company Safetech floats shares amid rising investor interest
Romania government to pursue “ambitious” timetable for justice reforms
Private finance mobilised by development banks up 9% to $175bn in 2019
EBRD and WBIF support fast broadband in rural Serbia
Slovenia plans region's longest-tenor Eurobond
Slovenian crypto payment system enters Thai market
Slovenia’s economic sentiment indicator up 2.2 pp m/m in January
Slovenia lost €10bn by neglecting wood industry for decades
Turkish groceries delivery app Getir goes online in London
D’S Damat franchise deals ‘show Turkey’s hard-pressed mall operators becoming their own tenants’
Turkey’s benchmark rate held as concerns over faltering recovery come to fore
Following war with Armenia, Azerbaijan gains control of lucrative gold mines
CAUCASUS BLOG : What can Biden offer the Caucasus and Stans, all but forgotten about by Trump?
Armenia ‘to extend life of its 1970s Metsamor nuclear power plant after 2026’
OUTLOOK 2021 Azerbaijan
OUTLOOK 2021 Georgia
“Try me” not telecoms minister Iran’s president tells hardliners in internet row
Iran’s President Khamenei menaces private citizen Trump
Iran’s technology minister indicted for failing to properly implement internet censorship
No US move to rejoin Iran nuclear deal imminent, say Biden national security nominees
COVID-19 and Trump’s indifference helped human rights abusers in 2020
Central Asia vaccination plans underwhelm, but governments look unruffled
Fears of authoritarianism as Kyrgyz populist wins landslide and backing for ‘Khanstitution’
COMMENT: Mongolia is an island of democracy
OUTLOOK 2021 Mongolia
Mongolia's PM quits amid protests over treatment of mother with coronavirus and newborn baby
Mongolia's winter dzud set to be one of most extreme on record says Red Cross
Tajikistan: Writing for the president is on the wall (and then scrubbed off)
OUTLOOK 2021 Turkmenistan
Turkmenistan: How the Grinch stole New Year
COMMENT: Uzbekistan is being transformed, but where are the democratic reforms?
Download the pdf version
More...
Russia was widely criticised when it was the first in the world to register the Sputnik V anti-coronavirus (COVID-19) vaccine in August, accused of rushing through the approval for political gain.
Since then, the whole development of the vaccine has been dogged by Schadenfreude as the press leapt on any signs of impropriety in the data and Russia has even been accused of stealing the technology.
But the markets jumped when the US pharmaceutical giant firm Pfizer, together with the German research company BioNtech, stated their version of the vaccine has a 90% efficacy, and investment banks immediately upgraded their 2021 outlooks for a scenario where some sort of normality returns.
In the meantime, Sputnik V’s clinical Phase III trials are half way through and no major problems with Sputnik have been thrown up yet. About half of the 40,000 volunteers in the trial have been given both shots to no major ill-effect. And the day after Pfizer’s announcement, the producers released preliminary results that show Sputnik V has a 92% efficacy.
“Everyone is sick and tired of all the COVID news flow in recent months but there has already been a lot of progress already made in the vaccine – and I’m not talking about US vaccine,” Sofya Donets, Renaissance Capital’s Russia and Commonwealth of Independent States (CIS) economist, said during the bank’s 25th anniversary investment summit last week. “In Russia we already have two vaccines that are registered: one back in August and then again in October. They will be ready soon for large-scale production.”
Donets is already including a scenario where mass vaccinations takes place and that pandemic fades away in the first half of next year.
“40,000 volunteers were already vaccinated during the testing period. By the end of this year producers are ready to supply 5-6mn doses per month and by spring officials report that will go up to 15mn per month: enough to vaccinate all Russians over the age of 60 in two months,” says Donets.
Russia Inc. goes into Big Pharma
Put aside for a moment the political one-upmanship that has dogged the global search for medicine to deal with a killer illness. Once the hype ends the business will begin. And this is going to be a very big business indeed.
Estimates of the value of the coronavirus vaccine market vary wildly with figures from $25bn to $100bn being bandied about. But clearly it will be worth multiple billions of dollars. And whoever gets a working vaccine to market first will capture a large slice of that money.
Kirill Dmitriev, the CEO of the sovereign wealth fund, the Russian Direct Investment Fund (RDIF) that financed much of the Sputnik V research, says he thinks Russia will control about a third of the eventual 3bn-5bn dose market. If that is true, then coronavirus vaccine exports will earn Russia as much as it gets from exporting grain or arms – and Russia is a global leader in both those export categories.
Russia Inc. as a Big Pharma concern is not exactly an image that we are used to, but given its prowess in the other sciences it certainly has the intellectual capital that could produce a working vaccine.
The problems Russia will face going forward will be ones of business. Production is already proving to be a major headache. Donets’ estimate for 5-6mn doses a month is already down on earlier predictions that 10mn doses would be produced by Christmas and the 15mn doses a month that could be produced in the first half of next year is half the earlier forecasts.
Last month, the RDIF said that it is currently investing into production facilities and will be able to produce 30mn doses by the end of this year and up to 200mn doses a year starting in 2021, but clearly it is not going as fast as the sovereign wealth fund had hoped for.
In mid-October, Industry Minister Denis Manturov, in an interview with Bloomberg, called these promises "nonsense." “The main challenge now is to scale production,” he said. "It is impossible to produce 30mn doses by the end of the year." The updated forecast of RDIF is 7-10mn doses of vaccine in December-January – and even this estimate is in doubt.
Nevertheless, millions of doses will be produced and the volume will rise rapidly as the problems are ironed out. With some $10bn of assets under management and the power of the Kremlin at its back the RDIF is not short of money or resources.
But Russia is. It doesn't have a well-developed and diversified pharmaceutical industry like that in the US that can be raided for resources and manpower.
However, Russia is doing a lot better on the distribution and marketing fronts. One of the big problems with the Pfizer vaccine is that it needs to be kept very cold.
Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said on November 11 that the distribution of Pfizer’s messenger RNA-based technology in developing countries is going to be “difficult” because it needs to be kept at -70C (-94F).
“It does have cold-chain challenges as it were. In a country like the UK and the United States we can address them and it still would be challenging; but probably much more challenging in countries in the developing world,” Fauci said at the Financial Times’ global pharmaceutical and biotechnology conference.
The Russian version has none of these problems, as it can be kept at room temperature.
The extreme cold storage will also make the Pfizer drug a lot more expensive.
Russian investment bank BCS Global Markets estimates that possible pricing of the vaccine for sales abroad could vary at about RUB300-1,000 per dose ($4-14), which is a fraction of estimates by the Financial Times of planned vaccine prices by foreign pharma majors’ leading candidates: Moderna $25-30/dose, Pfizer/ BioNTtech $19.5 and AstraZeneca $3-4, although the last is on a par with the Russian cost.
Russia is also well ahead on the marketing and sales. In August almost immediately after Sputnik V was registered, the producers signed a deal with Kazakhstan to supply several million doses as soon as clinical trials were over.
Uzbekistan has also signed a deal with Russia for 30mn doses, as have several BRIC countries. In all, some 50 countries have reportedly signed some sort of deal with Russia to buy its vaccine. For countries like Kazakhstan and Uzbekistan driving vaccine doses around their huge countries that have to be kept at -70C is a non-starter. Plus following its “Moscow consensus” ideology the Kremlin will package sales of vaccine doses together with other things like energy and politics to make up an offer that appeals to countries like these that a commercial entity like Pfizer can’t match.
“We expect that Russia will move on domestic vaccine and will already start exporting the vaccine in the first half of 2021. 20 countries are in discussions with Russian producers,” says Donets. “The India potential contract is for 100mn doses as well as LatAm countries [and] as well as Russia’s regional neighbours.”
Just these named deals add up to something around $500mn, which is half of the RDIF’s Dmitriev’s guess that Russia could take $1bn of the total $3bn-$5bn market.
Register here to continue reading this article and 5 more for free or purchase 12 months full website access including the bne Magazine for just $250/year.
Register to read the bne monthly magazine for free:
Already registered
Password could contain only a-z0-9\+*?[^]$(){}=!<>|:-_ characters and have 8-20 symbols length.
Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.
Forgotten password?
Email field can't be empty.
No user with this email address.
Access recovery request has expired, or you are using the wrong recovery token. Please, try again.
Access recover request has expired. Please, try again.
To continue viewing our content you need to complete the registration process.
Please look for an email that was sent to with the subject line "Confirmation bne IntelliNews access". This email will have instructions on how to complete registration process. Please check in your "Junk" folder in case this communication was misdirected in your email system.
If you have any questions please contact us at sales@intellinews.com
Sorry, but you have used all your free articles fro this month for bne IntelliNews. Subscribe to continue reading for only $119 per year.
Your subscription includes:
For the meantime we are also offering a free subscription to bne's digital weekly newspaper to subscribers to the online package.
Click here for more subscription options, including to the print version of our flagship monthly magazine:
More subscription options
Take a trial to our premium daily news service aimed at professional investors that covers the 30 countries of emerging Europe:
Get IntelliNews PRO
For any other enquiries about our products or corporate discounts please contact us at sales@intellinews.com
If you no longer wish to receive our emails, unsubscribe here.
Magazine annual electronic subscription
Magazine annual print subscription
Website & Archive annual subscription
Combined package: web access & magazine print annual subscription